• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Coronavirus > 5 things to know this week in life sciences: Week of Dec. 7

5 things to know this week in life sciences: Week of Dec. 7

Dec. 9, 2020 by Steve Kemler and Adam Lohr

  • email
  • Twitter
  • Facebook
  • Linkedin

COVID-19 vaccine news continues to dominate headlines as candidates from several companies move closer to obtaining emergency use authorization from the Food and Drug Administration. Also on the drug approval front, tech giant Palantir and the FDA entered into a $44 million deal for the agency to use the company’s software in its review process. Plus, we take a look at recent developments in telemedicine therapies, sickle cell disease treatments and permanent changes to clinical trials as a result of the pandemic.

This is the first installment of a new weekly roundup in which we highlight five things you need to know about in the life sciences industry. Here’s the latest.

FDA is confident in results of Pfizer/BioNTech COVID-19 clinical trial

The biggest news this week is the FDA’s endorsement of the Pfizer/BioNTech COVID-19 vaccine. In documents released Tuesday, FDA reviewers called the vaccine “highly effective,” as this article from STAT reports.

The FDA will have an advisory committee review of the vaccine on Thursday, another step in determining whether the vaccine will be approved for emergency use in the United States. In the UK, the first doses have begun to be administered. There may, finally, be some light at the end of the pandemic tunnel.

(Bonus reads: The AstraZeneca/Oxford vaccine results are good, but not as positive as the Pfizer or Moderna vaccines, this STAT piece explains. Plus, how will distribution of a vaccine really work?)

The lines between tech and life sciences continue to blur with Palantir deal

The FDA has entered into a new agreement with tech giant Palantir to use its technology to enhance the tools used in drug reviews and inspections.

When pharmaceutical companies submit information to the FDA for drug approval, the agency performs its own statistical analysis to vet the potential drug. This $44 million deal means the Center for Drug Evaluation and Research (CDER) and Oncology Center of Excellence – both part of the FDA – will leverage Palantir software tools to support their drug analysis and recommendations.

Pear Therapeutics scores an $80 million series D round for digital therapies

Digital therapeutics company Pear Therapeutics’ whopping $80 million funding round is one of the latest examples of how the pandemic is driving adoption of new technologies and fueling the growth of existing remote treatment options such as telemedicine.

Pear has a number of telemedicine treatments for both addiction and insomnia. Financing deals such as this one demonstrate that, although the pandemic will one day come to an end, more widespread adoption of telemedicine is here to stay.

Bluebird Bio presents a promising treatment for sickle cell disease

Historically, there have been poor treatment options for people with sickle cell disease, but several companies are making progress toward new therapies. CRISPR Therapeutics and Vertex Pharmaceuticals announced results of their CTX001 trial earlier this month, followed by news of promising results from Bluebird Bio’s sickle cell gene therapy clinical trial (though it’s important to note that the study is small). The fact that multiple companies have recently achieved positive results is a welcome development for a disease that has had limited options in the past.

Video: Technical innovations are reducing clinical trial risks

2020 has forced contract research organizations and sponsors to rethink how they execute on clinical trials. These changes were driven by necessity, but are here to stay even as the clinical trial environment eventually returns to some semblance of normal. In this video, sponsors and CRO leaders discuss how the pandemic has forced clinical trials to become more flexible, what we have learned in 2020 and which changes will have longevity.

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • Coronavirus pandemic highlights importance of life sciences industry

    While the coronavirus pandemic has slowed growth in the life sciences sector this year, it has also highlighted the importance of the biotech and pharmaceutical industries as the whole world battles the COVID-19 disease and its impacts. This…

  • Life science graphic
    Better data use has pros and cons for life sciences

    The volume and variety of health care data should expand significantly in 2019. Specifically, we will be monitoring growth in data sources outside those collected from traditional electronic health records, including information gleaned from wearable technology and direct-to-consumer…

  • Life sciences industry growth was on a strong trajectory. Then the coronavirus pandemic hit.

    Strong consumer spending, historically low unemployment and an easing of trade tensions with China initially fueled optimism early in the year for a 2020 bull market. But as the coronavirus pandemic has upended the global economy, uncertainty and…

Filed Under: Coronavirus, Life Sciences Tagged With: coronavirus, Covid-19, covid-19 vaccine, life sciences, pharmaceuticals, research

About Steve Kemler

Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.

As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.

In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

About Adam Lohr

Adam is an audit partner and life sciences senior analyst in RSM's cutting-edge industry eminence program. In addition to providing assurance services to his clients, he sits on RSM’s national life science team and leads the San Diego office life science practice.

His senior analyst responsibilities include advising the firm’s life sciences care clients and client servers as they work to navigate the rapidly changing industry environment. Adam regularly writes, presents and advises on capital markets, digital transformation, policy and other issues transforming life sciences. He is an instructor at the regional and national level, and is experienced in the application of ASC 606 revenue recognition for the technology and consumer products industries.

Adam has over 12 years of accounting and finance experience, serving private equity-backed and private closely held companies in the middle market. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their business.

Primary Sidebar

Read RSM analysts’ industry coverage of coronavirus.

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Life Science articles

5 things to know in life sciences: Week of Jan. 18

Jan. 21, 2021

5 things to know this week in life sciences: Week of Jan. 11

Jan. 15, 2021

This year may be the busiest ever for health care and life sciences deal volume

Jan. 12, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences